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outbreak of severe gastroenteritis in a litter
in Sweden
David Sutton1*, Carina Vinberg2, Agneta Gustafsson3, Jacqueline Pearce1 and Neil Greenwood1Abstract
A litter of recently-vaccinated puppies in Sweden experienced signs of severe haemorrhagic gastroenteritis. Canine
parvovirus (CPV) was suspected as the cause of this outbreak on the basis of the clinical signs and the presence of
parvoviral antigen in the faeces from one of the affected pups - confirmed using a commercial in-clinic faecal
antigen ELISA test kit. A concern was raised about whether the vaccine (which contained a live, attenuated strain of
CPV) could have caused the disease and so further faecal samples from the affected pups were submitted for
laboratory virus isolation and identification.
On cell culture, two out of four faecal samples were found to be virus-positive. This was confirmed as being canine
parvovirus by immuno-staining with CPV specific monoclonal antibody. The virus was then tested using a series of PCR
probes designed to confirm the identity of CPV and to distinguish the unique vaccine strain from field virus. This
confirmed that the virus was indeed CPV but that it was not vaccine strain. The virus was then typed by sequencing
the 426 amino acid region of the capsid gene which revealed this to be a type 2c virus.
Since its emergence in the late 1970s, canine parvovirus 2 (CPV2) has spread worldwide and is recognised as an
important canine pathogen in all countries. The original CPV2 rapidly evolved into two antigenic variants, CPV2a and
CPV2b, which progressively replaced the original CPV2. More recently a new antigenic variant, CPV2c, has appeared. To
date this variant has been identified in many countries worldwide but there have been no reports yet of its presence in
any Scandinavian countries. This case report therefore represents the first published evidence of the involvement of
CPV2c in a severe outbreak of typical haemorrhagic gastroenteritis in a susceptible litter of pups in Scandinavia.
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Canine parvovirus 2 (CPV2) emerged during the late
1970s, probably as a result of mutation of feline parvovirus
or a related parvovirus of wild carnivores [1]. CPV2
showed relatively rapid genetic evolution and within only
a few years the first antigenic variants, CPV2a and CPV2b,
appeared [2,3]. These variants replaced the original type 2
virus in the field, and from the mid-1980s until 2000 the
presence of CPV2a and/or CPV2b isolates was widespread
in all countries, although the relative proportions of these
two types varied from country to country [1-8]. In 2000, a
new variant, now referred to as CPV2c, was identified in
Italy [9]. This new variant has since been identified in* Correspondence: david.sutton@merck.com
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stated.many other countries worldwide but the earliest evidence
of its presence (based on retrospective testing) is from
1996 in Germany [10]. Despite CPV2c having now be-
come established in geographically distinct countries
worldwide, and in some countries (e.g. Italy, Argentina,
Uruguay) having become the most frequently isolated
variant [10-13], there are still countries where it has appar-
ently not yet established. In the UK, for instance, apart
from the discovery of a single isolate from Scotland, recent
analysis of isolates from a large cross-sectional sample of
UK dogs over a two year period with severe diarrhoea re-
vealed the presence of 2a and 2b but not 2c [14]. Up until
now there have been no isolates of CPV2c reported from
Sweden, or any other Scandinavian country. The case
reported here is of a severe outbreak of haemorrhagic
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isolation and typing in order to confirm whether this
was vaccine strain it was found to be a field strain of
type 2c. This is believed to be the first report of the con-
firmation of the identification of CPV2c from a clinical
case in Scandinavia.
Case presentation
History and clinical signs
A two year old, mixed breed, collie x berner sennen
bitch, with an unknown vaccination status was taken to
an animal hospital after a few days of vomiting and an-
orexia. The bitch was thin and in poor condition, with a
brownish, malodourous discharge from the vulva. Preg-
nancy was confirmed with x-ray and the stage of gesta-
tion was estimated to be at least day 61 with at least 13
puppies. Abdominal ultrasound showed that at least two
pups had a low heart rate (120–150). As a consequence
of the poor condition of the bitch, and the deteriorating
condition of the puppies, it was decided to perform a
caesarean section followed by ovariohysterectomy and
14 live puppies were delivered in this way.
Post-operatively, the bitch was tired and unwilling to
allow the puppies to feed. The litter was therefore hand-
reared from birth using formula milk. (Babydog Milk -
Royal Canin). The bitch and puppies went home later the
same day, but the bitch was re-hospitalised the following
day with fever (41°C) and signs of vomiting and diarrhoea
but no signs of bleeding. On examination she was found
to have pale mucosae, an elevated heart rate (150 beats/
minute), a weak pulse and low blood pressure. She was
admitted to the hospital intensive care unit, and treated
with antibiotics, aggressive intravenous fluid therapy and
plasma, but continued to deteriorate. Abdominal ultra-
sound showed that several sections of the intestine were
corrugated and that the gastric wall was moderately hyper-
trophic with free abdominal fluid. Despite intensive treat-
ment for some hours her condition continued to worsen
and so later that day she was euthanized.
The puppies were placed in a foster home and bottle-
fed with formula milk. As the bitch had not suckled the
puppies they had never received colostrum. After the
bottle-feeding period, the puppies were given puppy
food (Science Plan Puppy: All breeds - Hills). Two of the
14 puppies had died at some point during their time in
the foster home but unfortunately no further details are
available concerning the age of these pups or what clin-
ical signs were seen prior to death. The 12 remaining
puppies were vaccinated at eight weeks of age with a
multivalent canine vaccine (Nobivac DHPPi – MSD Ani-
mal Health) containing live attenuated strains of canine
distemper virus, canine adenovirus 2, canine parvovirus
2 and canine parainfluenza virus. They were transferred
to their new homes two days later.According to information from the foster home, all 12
puppies became ill with signs of gastroenteritis within five
days of being rehomed. Eight of the puppies were admit-
ted for care at the animal hospital. The four remaining
puppies had milder signs and were treated symptomatic-
ally at home or by their local veterinarian. No further in-
formation is available concerning these puppies.
For the eight hospitalized puppies, the onset of cli-
nical signs was between four and seven days after vac-
cination. Four of these puppies were admitted six days
after vaccination and four were admitted seven to
ten days after vaccination. All the puppies showed a
similar clinical picture; they were mildly to moderately
dehydrated with dry mucous membranes, normal heart
and lung sounds and signs of mild to moderate pain on
abdominal palpation. At time of admission their body
temperatures varied between 38.1-39.4°C and three
puppies subsequently showed pyrexia with tempe-
ratures of 39.7-40.5°C. All puppies were vomiting a
watery, sometimes haemorrhagic, fluid and passing a
voluminous watery haemorrhagic mucoid diarrhoea
several times a day. In addition some of the puppies had
ascarids in the vomitus and diarrhoea.
All the puppies were given intravenous fluid therapy
with lactated Ringer’s solution and Ringer’s with glu-
cose. Seven of them were also given plasma infusions.
They were also all given intravenous antibiotic therapy
(ampicillin which in three cases were changed to
cefuroxime). Five puppies were followed on leukogram
and all five showed marked leucopenia and neutropenia,
which had normalized before discharge. All puppies
survived and hospitalization times ranged from 4–
16 days (median 6 days).
Virus identification and isolation
A faecal sample taken by the referring veterinarian from
one puppy one day after the onset of clinical signs tested
positive for parvovirus (Witness CPV Canine Parvovirus
Antigen Test Kit - Pfizer). At the animal hospital, faecal
samples were collected from four puppies (4–5 days
after the onset of clinical signs) and stored at +8°C for
about three months prior to being sent for laboratory
analysis. Three of the samples (1, 2 and 3) were of a li-
quid consistency and were diluted in phosphate buffered
saline (PBS), vortexed and filtered through a 45 μ filter.
The fourth sample (4) was of a hard consistency how-
ever, and was homogenized with phosphate buffered sa-
line (PBS) prior to filtering. All samples were examined
for CPV content by growth in tissue culture on canine
A72 cells, and also by the polymerase chain reaction
(PCR) using primers specifically designed to enable dif-
ferentiation of the CPV vaccine strain that is used in
DHPPi (strain 154att), and all other vaccines and field
CPV field viruses.
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the time of cell seeding and incubated at 37°C for four
days. Cultures were examined daily for evidence of a de-
veloping cytopathic effect (cpe) and also by a haemag-
glutination assay (HA) using porcine erythrocytes.
Although an obvious cpe was not observed, one isolate
(4) was HA positive indicating the presence of CPV. As
the cultures had reached cell confluency, a second viral
pass was made by trypsinisation of the cell monlayer
and splitting the culture into new flasks. On the second
pass another sample (3) was HA positive and showed a
cpe typical of CPV. All pass 2 cultures were harvested
and titrated on A72 cells on 96 well plates for confirm-
ation of CPV isolation. After incubation for 4 days at
37°C the cells were fixed with methanol and im-
munologically stained with a CPV specific monoclonal
primary antibody and an anti-mouse conjugated (Fluor-
escein-isothiocyanate) secondary antibody. The two
samples (3 and 4) gave positive immuno-staining of
infected cells confirming the isolation of CPV, whereas
the two HA negative samples (1 and 2) were also nega-
tive for isolation by immuno-staining.
Virus typing
The sample filtrates were boiled for five minutes,
cooled on ice, and 200 μl sample taken for purification
and isolation of DNA template on a Qiagen QIA quick
PCR clean up column according to the suppliers’
protocol. DNA was eluted from the column with 50 μl
elution buffer and 5 μl used in a 50 μl Qiagen Hot-
StarTaq master mix PCR reaction. The four sample
templates were used in three different PCR reactions
that are used routinely for the characterisation of
clinical samples submitted where CPV infection is
suspected. The PCRs have been designed to firstly de-
tect the presence of CPV and secondly to differentiate
the vaccine strain used in DHPPi, namely 154att, and
all other CPVs.
PCR 1: detection of vaccine virus
The specific detection of the 154att vaccine virus was
made using primers located upstream of the VP2 gene;
a forward primer specific to the vaccine sequence and a
universal conserved reverse primer. In an extensive
survey (unpublished), the vaccine specific sequence
was not detected in over one hundred field viruses
(types 2, 2a, 2b and 2c) collected from dogs with clin-
ical parvovirus disease, many CPV vaccines or pub-
lished non-structural sequences.
PCR 2: detection of non-154att vaccine virus
The detection of non-154att CPVs was made by re-
placing the 154att specific primer in PCR 1 with a con-
served forward primer.PCR 3: detection of all CPV types
Detection of all CPV types was made using conserved
forward and reverse primers that amplified a 461 bp
product that encapsidates the 426 amino acid residue.
PCR1, 2 and 3 were performed as follows: an initial
denaturation step at 95°C for 15 mins, followed by 5 -
cycles of 94°C for 45 s, 45°C for 45 s and 72°C for
1 min, then 28 cycles of 94°C for 45 s, 50°C for 45 s and
72°C for 1 min, and a final extension step at 72°C for
10 mins.
In our experience the diagnostic PCRs described are
as sensitive as viral isolation in tissue culture for the de-
tection of CPV, and also have the advantage of a rapid
diagnosis of disease.
Following PCR the samples were electrophoresed on a
0.8% agarose submarine gel containing ethidium brom-
ide (Tris Borate EDTA running buffer) and an image
recorded on a Biorad Gel Doc. All samples were positive
for CPV and field virus; positive in PCR 2 and 3 respect-
ively. However all samples were negative for the 154att
strain in PCR 1. As the 154att vaccine was not detected
this indicated that the CPV was most probably a field
virus. Although the PCRs described enable the detection
of CPV and the differentiation of vaccine (154att strain)
from all other CPVs, they do not enable determination
of the CPV antigenic type.
To determine the antigenic type of the isolates, the
PCR 3 product was purified using a Qiagen QIA quick
column and sequence determined on both strands on a
ABI 3170XL instrument. Sequence alignments were
made with reference CPV type 2, 2a, 2b and 2c se-
quences using Clone Manager version 11. These align-
ments showed that all four samples had a Glu at position
426 of the capsid and were therefore typed as CPV2c.
Alignment of the Swedish VP2 with three Italian CPV2c
isolates (Accession nos. FJ222821, FJ005233, GU362935)
and one German CPV2c isolate (FJ005198) showed that
the amino acid sequences were the same. However, the
Swedish VP2 had a silent change at residue 364 (Alanine)
with a GCA in place of GCG.
To confirm the CPV 2c typing of the isolates, prepara-
tions of the original faecal sample material were remade
and DNA purified as described. The whole VP2 capsid
gene was amplified in PCR4 using primers EF (forward)
and JS2 (reverse) in a 50 μl reaction using Qiagen
LongRange according to manufacturer’s instructions.
Following an initial denaturation step at 93°C for 3 mins,
amplification was carried out following 35 cycles of 93°C
for 15 s, 52°C for 30s and 68°C for 2 mins. Sequence
was determined on both strands confirming that all the
isolates were identical and indeed CPV2C.
To address the possibility of cross contamination, all
work was carried out to ‘good laboratory practice’ and
non-infected cell controls and no DNA reagent controls
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assays respectively.
Primer oligonucleotides used for amplification of capsid
VP2 and sequence determination are detailed in Table 1.
Conclusions
This case report raises a number of interesting issues.
First, although a full diagnostic screen for other patho-
gens was not undertaken, the presence of a field isolate
of CPV in faecal samples taken from a number of the
pups which were showing signs of severe haemorrhagic
gastroenteritis at the time would normally be considered
sufficient evidence to conclude that this was indeed an
outbreak of parvoviral enteritis [17,18].
The source of the infection is not known but from the
fact that the timing of onset of clinical disease was 2–
5 days after the pups had been transferred from the foster
home to their various new homes this makes it certain
that the pups must have become infected at the foster
home, and probably just before leaving bearing in mind
the usual incubation period of 3–5 days for canine parvo-
virus [19]. It is not known whether there was a sick dog at
the foster home at around this time, or if someone at the
home had either been in contact with a clinical case or
otherwise picked up infected material but these would be
the usual explanations for the source of infection.
Although the vaccination history of the bitch was un-
known, the pups had been vaccinated with a parvovirus-
containing multivalent vaccine (Nobivac DHPPi – MSD
Animal Health) a few days before the onset of signs in
the majority of pups. There has been some debate about
whether vaccination – especially with vaccines based on
the original ‘type 2’ virus – will protect as effectively
against the more recent subtypes, especially the 2b and
2c variants, although a number of studies have shown
evidence of cross-protection in this respect [20-23]. In
this case however it is clear from the timing of the onset
of clinical signs that the pups were already incubating
infection and that also the vaccine would probably not
have had a chance to stimulate a protective immunity
(the manufacturers claim a 7–10 day onset of immunity
post-vaccination). Therefore in this case vaccination
could not have been expected to be effective.
As regards vaccine efficacy, another caveat when vac-
cinating pups younger than around 3 months of age is
the possibility of interference from maternally-derivedTable 1 Primer oligonucleotides used for amplification of cap




JS2R CCACCCACACCATAACAACAantibody (MDA) which is transferred from the bitch
mainly via the colostrum shortly after birth. Following a
normal parturition and post-parturient period, puppies
would normally be expected to have acquired reasonable
levels of MDA - assuming that the bitch had a reasonable
level of immunity to parvovirus - and should be protected
against disease for the first few weeks of life [24]. In this
case however, with the history of no intake of colostrum, it
can reasonably be assumed that the pups would have had
minimal, if any, levels of MDA and should probably have
been vaccinated much earlier than 8 weeks of age. In this
respect in cases where MDA is known to be low, vaccin-
ation of the pups from at least six weeks and possibly four
weeks of age has been suggested [25-27]. Although the
use of many canine parvovirus vaccines at such a young
age is strictly ‘off label’ there are some so-called ‘puppy
vaccines’ which have been shown to be safe at these ages
and can therefore be used in this way in line with the
manufacturer’s recommendations.
Although the CPV isolate from the pups was con-
firmed as a CPV type 2c, and therefore was not the vac-
cine strain, one common concern of many owners and
veterinarians in cases where recently-vaccinated pups
show signs of typical clinical disease would be whether
the live vaccine virus could have reverted to virulence
and be responsible for the outbreak of disease [28]. In
this case, this was indeed the main reason that the virus
was sent for further identification following the initial
confirmation of the presence of CPV in the faeces using
an in-clinic test kit. Quick test kits can detect the pres-
ence of parvovirus but will not be able to distinguish the
type involved. In order to confirm whether the isolate is
a field strain or vaccine strain it is often sufficient to
type the virus since the original ‘type 2’ virus is no lon-
ger present in the field [2] and many vaccines (as was
the case here) are based on a type 2 strain. In such cases
the identification of either type 2a, 2b or 2c would be
sufficient to confirm a field infection. In this case the
manufacturers were initially able to use specific PCR
probes to differentiate between the unique genetic fin-
gerprint of the vaccine strain and all other CPV strains,
thus confirming that the isolate was not vaccine strain.
Follow-up typing was then used to determine that the
isolate was in fact a type 2c.
CPV2c has been reported as the most recent type of
CPV to have evolved and was first discovered in Italy insid VP2 and sequence determination
Position in 154att Fragment size Reference
R 4090 461 MSD AH
F 3629 MSD AH
F2748 2051 [15]
R 4799 [16]
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many other countries worldwide [11,29] but to date
there have been no reports of its presence in Sweden, or
any other Scandinavian countries. This case report
therefore represents the first published evidence of the
involvement of CPV2c in a severe outbreak of typical
haemorrhagic gastroenteritis in a susceptible litter of
pups in Scandinavia.
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